http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020509032-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-567 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0056 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-575 |
| filingDate | 2018-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2020509032-A |
| titleOfInvention | Combination administration of glucocorticoid receptor modulator and CYP3A inhibitor |
| abstract | Applicants provide methods of treating diseases including Cushing's syndrome and hormone-sensitive cancers by co-administration of a glucocorticoid receptor modulator (GRM) and a steroidogenic inhibitor and co-administration of a GRM and a CYP3A inhibitor. The GRM can be, for example, mifepristone; the CYP3A inhibitor or steroidogenic inhibitor (collectively, "inhibitors") can be, for example, ketoconazole or itraconazole. Inhibitors can cause toxicity or other serious adverse reactions; co-administration of inhibitors with other drugs may increase the risk of such toxic and adverse reactions due to inhibitors and / or other drugs. Applicants have surprisingly found that GRM can be administered to subjects receiving inhibitors without increasing the risk of adverse reactions. |
| priorityDate | 2017-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 375.